Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) have been given an average rating of “Moderate Buy” by the seven ratings firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $16.71.

OCUL has been the topic of several recent analyst reports. HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of Ocular Therapeutix in a report on Tuesday, December 3rd. Scotiabank started coverage on Ocular Therapeutix in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $22.00 price target on the stock.

Insider Buying and Selling at Ocular Therapeutix

In other Ocular Therapeutix news, insider Jeffrey S. Heier sold 2,948 shares of the stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $9.01, for a total value of $26,561.48. Following the sale, the insider now owns 269,059 shares of the company’s stock, valued at $2,424,221.59. This trade represents a 1.08 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 3.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Ocular Therapeutix

Large investors have recently made changes to their positions in the company. Bank of New York Mellon Corp grew its holdings in Ocular Therapeutix by 49.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 495,635 shares of the biopharmaceutical company’s stock worth $3,390,000 after acquiring an additional 164,383 shares in the last quarter. Banco Santander S.A. increased its holdings in Ocular Therapeutix by 81.3% in the second quarter. Banco Santander S.A. now owns 377,368 shares of the biopharmaceutical company’s stock valued at $2,581,000 after buying an additional 169,172 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Ocular Therapeutix by 757.9% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 32,044 shares of the biopharmaceutical company’s stock valued at $219,000 after buying an additional 28,309 shares in the last quarter. Atlas Capital Advisors LLC purchased a new stake in Ocular Therapeutix during the 2nd quarter worth about $34,000. Finally, Aptus Capital Advisors LLC acquired a new position in shares of Ocular Therapeutix during the 2nd quarter worth about $1,798,000. 59.21% of the stock is currently owned by hedge funds and other institutional investors.

Ocular Therapeutix Stock Down 1.2 %

Shares of OCUL opened at $8.44 on Friday. The company’s 50-day moving average price is $9.74 and its 200 day moving average price is $8.72. Ocular Therapeutix has a 12-month low of $3.76 and a 12-month high of $11.77. The company has a current ratio of 13.01, a quick ratio of 12.94 and a debt-to-equity ratio of 0.19. The firm has a market cap of $1.33 billion, a P/E ratio of -6.39 and a beta of 1.19.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.